The results revealed that abemaciclib, the first CDK4/6 inhibitor used in combination with endocrine therapy, can significantly enhance the invasive disease-free survival (IDFS) in patients with node-positive HR+/HER2-breast cancer who are at a high risk of early recurrence (Johnston et al., 2023). Here, ERBB2 is linked to breast cancer.